Metformin Hydrochloride

Metformin Hydrochloride is an oral antidiabetic that targets glucose metabolism in type 2 diabetes and related metabolic disorders.

• Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels.
• Prediabetes (impaired glucose tolerance): helps delay progression to overt diabetes.
• Polycystic ovary syndrome (off‑label): improves insulin sensitivity and may restore ovulatory function.

• Metformin Hydrochloride primarily inhibits hepatic gluconeogenesis, reduces intestinal glucose absorption, and enhances peripheral insulin sensitivity by activating AMP‑activated protein kinase (AMPK). These actions collectively decrease circulating glucose without stimulating insulin secretion.

Metformin Hydrochloride may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Diarrhea: loose stools, often early in therapy.
• Abdominal discomfort: cramping or bloating.
• Metallic taste: transient alteration of taste perception.
• Loss of appetite: reduced desire to eat.
• Vitamin B12 deficiency: long‑term use may lower B12 levels.

Serious or Rare Side Effects

• Lactic acidosis: rare but life‑threatening metabolic acidosis.
• Severe skin reactions: such as Stevens‑Johnson syndrome.
• Hepatotoxicity: liver injury in susceptible individuals.
• Hypoglycemia: when combined with insulin or secretagogues.
• Pancreatitis: inflammation of the pancreas.
• Acute renal failure: especially in dehydration or renal impairment.

Metformin Hydrochloride requires careful assessment before and during therapy.

• Renal function assessment: evaluate eGFR prior to initiation and periodically thereafter.
• Hepatic function monitoring: avoid use in patients with significant liver disease.
• Lactic acidosis risk: discontinue if patient develops severe infection, hypoxia, or acute heart failure.
• Pregnancy and lactation: use only if benefits outweigh potential risks.
• Drug interaction review: assess concomitant medications that may affect renal clearance.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Metformin Hydrochloride can interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid)

• Iodinated contrast agents: may precipitate acute renal failure and lactic acidosis.
• Cimetidine: can increase metformin plasma concentrations.
• Alcohol excess: heightens risk of lactic acidosis.
• Other biguanides: additive risk of toxicity.
• Renal‑impairing drugs: such as NSAIDs, may reduce metformin clearance.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may mask hypoglycemia symptoms.
• Diuretics: can affect renal function and electrolyte balance.
• ACE inhibitors/ARBs: monitor renal parameters.
• Calcium channel blockers: may modestly increase metformin levels.
• Sulfonylureas: combined therapy raises hypoglycemia risk.